Serum squamous cell carcinoma antigen is a predictive factor of outcomes in patients with locally advanced unresectable esophageal squamous cell carcinoma treated by definitive chemoradiotherapy

Abstract

Aim: Definitive chemoradiotherapy (dCRT) is the standard treatment for locally advanced unresectable esophageal squamous cell carcinoma (LU-ESCC). This study aimed to describe the results of dCRT for T4 ESCC and evaluate the pretherapeutic predictive factors of the outcomes.

Methods: A total of 133 patients with T4 ESCC who received dCRT were grouped into those who achieved a complete response (CR) or those who had residual disease (RD). The clinicopathologic variables were compared between the groups and the overall survival (OS) was evaluated. The predictive factor of RD was assessed and the prognostic factor for OS was identified.

Results: Among the 133 patients, 31 (23%) achieved CR. The CR group had a significantly better OS than the RD group (89.9 months vs. 10.7 months; hazard ratio = 0.096; 95% confidence interval: 0.05-0.19; P < 0.001). Multivariate analysis showed that a supracarinal tumor (OR = 3.21; P = 0.016), higher pretherapeutic serum SCC-Ag level (> 1.6 ng/mL) (OR = 2.86; P = 0.018), and metastatic node invasion (OR = 3.19; P = 0.048) were independent predictors of RD. The increased level of pretherapeutic serum squamous cell carcinoma antigen (> 1.6 ng/mL) (OR = 1.61; P = 0.022) was an independent predictor of poor survival.

Conclusions: Among the patients who underwent dCRT for LU-ESCC, 23% achieved CR, and the long-term outcome of these patients was favorable. Increased levels of pretherapeutic serum squamous cell carcinoma antigen were also found to be predictive of treatment failure.

Keywords

Esophageal cancer / chemoradiotherapy / esophageal squamous cell carcinoma / predictive factor

References

[1] GLOBOCAN database. Available from: http://gco.iarc.fr/. [Last accessed on 19 Jan 2022]

[2] Sasaki Y,Koyama R,Adachi Y.Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing.World J Gastroenterol2016;22:2284-93 PMCID:PMC4735002

[3] Seto Y,Gomi K.Treatment of thoracic esophageal carcinoma invading adjacent structures.Cancer Sci2007;98:937-42

[4] Tachimori Y,Numasaki H.Registration Committee for Esophageal Cancer of the Japan Esophageal SocietyComprehensive registry of esophageal cancer in Japan, 2012.Esophagus2019;16:221-45 PMCID:PMC6592979

[5] Toh Y,Tachimori Y.Current status of radiotherapy for patients with thoracic esophageal cancer in Japan, based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.Esophagus2020;17:25-32

[6] Ohtsu A,Muro K.Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.J Clin Oncol1999;17:2915-21

[7] Kitagawa Y,Oyama T.Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2.Esophagus2019;16:25-43 PMCID:PMC6510875

[8] Ishida K,Yamamoto S,Shinoda M.Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).Jpn J Clin Oncol2004;34:615-9

[9] Shinoda M,Kato K.Japan Clinical Oncology GroupRandomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).Cancer Sci2015;106:407-12 PMCID:PMC4409884

[10] Sugawara K,Okumura Y.Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma.Int J Clin Oncol2020;25:552-60

[11] Okamura A,Mayanagi S.Clinical significance of pretherapeutic serum squamous cell carcinoma antigen level in patients with neoadjuvant chemotherapy for esophageal squamous cell carcinoma.Ann Surg Oncol2021;28:1209-16

[12] Suzuki T,Watanabe M.Neoadjuvant chemoradiotherapy with cisplatin plus fluorouracil for borderline resectable esophageal squamous cell carcinoma.Ann Surg Oncol2020;27:1510-7

[13] McMillan DC,O'Gorman P,McArdle CS.Performance status of male and female advanced cancer patients is independently predicted by mid-upper arm circumference measurement.Nutr Cancer2002;42:191-3

[14] Brierley JD,Wittekind C. TNM classification of malignant tumors. International union against cancer. 8th ed. Oxford: Wiley; 2017.

[15] Kanda Y.Investigation of the freely available easy-to-use software 'EZR' for medical statistics.Bone Marrow Transplant2013;48:452-8 PMCID:PMC3590441

[16] Shimada H,Okazumi S.Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma.Surgery2003;133:486-94 PMCID:PMC3590441

[17] Okamura A,Mine S.Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.Dis Esophagus2017;30:1-8

[18] Suminami Y,Vujanovic NL,Kato H.Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1.Br J Cancer2000;82:981-9 PMCID:PMC2374407

[19] Murakami A,Hirakawa H,Numa F.Squamous cell carcinoma antigen suppresses radiation-induced cell death.Br J Cancer2001;84:851-8 PMCID:PMC2363809

[20] Luke CJ,Askew YS.An intracellular serpin regulates necrosis by inhibiting the induction and sequelae of lysosomal injury.Cell2007;130:1108-19 PMCID:PMC2128786

[21] Markovina S,Henke LE.Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer.Br J Cancer2018;118:72-8 PMCID:PMC5765231

[22] Sakai M,Sano A.Significance of lymph node capsular invasion in esophageal squamous cell carcinoma.Ann Surg Oncol2012;19:1911-7

[23] Lagarde SM,Gisbertz SS.Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy.Br J Surg2016;103:1658-64

[24] Yokota T,Hamamoto Y.A 3-year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer.Ann Surg Oncol2020;27:460-7

[25] Terada M,Daiko H.Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE).Jpn J Clin Oncol2019;49:1055-60

[26] Higuchi K,Tanabe S.Kitasato Digestive Disease and Oncology GroupDefinitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).Int J Radiat Oncol Biol Phys2014;89:872-9

[27] Tamaki Y,Nakajima M.Concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil improves survival of patients with advanced esophageal cancer compared with conventional concurrent chemoradiotherapy with cisplatin and 5-fluorouracil.J Cancer2018;9:2765-72 PMCID:PMC6096357

[28] Hamamoto Y,Aoki Y.Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma.Esophagus2017;14:324-32 PMCID:PMC5603637

[29] Yokota T,Kato H.Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer.Int J Clin Oncol2018;23:73-80